A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat   mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in   BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC):   CheckMate 9UT.

Document type:: Meeting Abstract
Author(s):: Hahn, Noah M.; Chang, Sam; Meng, Maxwell; Shore, Neal D.; Konety, Badrinath R.; Steinberg, Gary D.; Gschwend, Juergen; Nishiyama, Hiroyuki; Palou, Joan; Taylor, John A.; Lambert, Alexandre; Zhu, Li; Maeda, Toshiki; Raybold, Bradley; Fischer, Bruce S.; Jeyamohan, Chandrika; Zardavas, Dimitrios; Witjes, Fred
Title:: A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 15
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: